---
document_datetime: 2024-12-10 17:26:00
document_pages: 12
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/aubagio-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
document_name: aubagio-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
version: success
processing_time: 9.0722645
conversion_datetime: 2025-12-28 04:33:43.094189
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## AUBAGIO

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                                                                                                  | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| IA/0048              | A.6 - Administrative change - Change in ATC Code/ATC Vet Code                                                                                                          | 17/09/2024                          |                                             | SmPC                             |           |
| IB/0047              | B.I.d.1.a.4 - Stability of AS - Change in the re-test period/storage period - Extension or introduction of a re-test period/storage period supported by real time data | 10/09/2024                          | n/a                                         |                                  |           |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| PSUSA/10135 /202309   | Periodic Safety Update EU Single assessment - teriflunomide                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | 30/05/2024   | 24/07/2024   | SmPC and PL           | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUSA/10135/202309.   |
|-----------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|-----------------------|----------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0046               | C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | 25/04/2024   | 24/07/2024   | SmPC, Annex II and PL |                                                                                                                                              |
| N/0044                | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 13/07/2023   | 24/07/2024   | PL                    |                                                                                                                                              |
| IA/0043               | B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | 16/05/2023   | n/a          |                       |                                                                                                                                              |
| II/0042               | Submission of the final report of the open-label extension period for study EFC11759, listed as a category 3 study in the RMP. This is a two-year, multicenter, randomized, double-blind, placebo- controlled, parallel group trial to evaluate efficacy, safety, tolerability and pharmacokinetics of teriflunomide administered orally once daily in pediatric patients with relapsing forms of multiple sclerosis (MS) followed by an open-label extension. The RMP version 8.1 has also been submitted. C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority | 14/04/2023   | n/a          |                       |                                                                                                                                              |
| T/0040                | Transfer of Marketing Authorisation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 31/10/2022   | 21/11/2022   | SmPC, Labelling and   |                                                                                                                                              |

<div style=\"page-break-after: always\"></div>

|           |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |            |            | PL              |                         |
|-----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------|-------------------------|
| IA/0041/G | This was an application for a group of variations. A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or | 24/10/2022 | n/a        |                 | manufacturer of a novel |
| II/0038   | Submission of the final PASS OBS12753 study report listed as a category 3 study in the RMP. This is a prospective cohort study of long-term safety of teriflunomide in multiple sclerosis patients in Europe. The updated RMP v 7.3 is agreed. C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority                                                                                                               | 13/01/2022 | n/a        |                 |                         |
| N/0039    | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                                                                                                                           | 23/11/2021 | 08/07/2022 | PL              |                         |
| IG/1386   | A.5.a - Administrative change - Change in the name and/or address of a manufacturer/importer responsible for batch release                                                                                                                                                                                                                                                                                                                                                                                 | 03/08/2021 | 08/07/2022 | Annex II and PL |                         |

<div style=\"page-break-after: always\"></div>

| PSUSA/10135 /202009   | Periodic Safety Update EU Single assessment - teriflunomide                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 20/05/2021   | 23/07/2021   | SmPC and PL                      | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUSA/10135/202009.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
|-----------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|----------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| X/0031/G              | This was an application for a group of variations. Annex I_2.(c) Change or addition of a new strength/potency C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 22/04/2021   | 17/06/2021   | SmPC, Annex II, Labelling and PL |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| IB/0036               | C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 11/02/2021   | n/a          |                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| II/0032               | C.I.4. Update of section 4.4 of the SmPC in order to update information on the liver monitoring schedule and the use of concomitant potentially hepatotoxic drugs based on evidence from diverse clinical and postmarketing sources including results from three studies, namely TENERE/EFC10891 (Phase 3 multi- center, randomized, double-blind, open-label (for IFN Î² -1a), parallel-group study), Teri-PRO/LPS13567 study (Phase 4, multicenter, prospective, single-arm, open-label study) and TERIKIDS/EFC11759 (Phase 3 multicenter, randomized, double-blind, placebo- controlled, parallel-group study in patients with 10 to 17 years of age), together with postmarketing data including real-world data from two European National Disease registries (The Danish Multiple Sclerosis | 21/01/2021   | 17/06/2021   | SmPC                             | Section 4.4 of the SmPC has been updated to inform about an update in liver monitoring. Liver enzimes should be assessed at least four weeks during the first 6 months and regularly thereafter. For patients with pre-existing liver disorders, concomitant use of potentially hepatotoxic drugs or those with signs or simtomps of liver injury, monitoring is recommended every two weeks during first 6 months and every 8 weeks thereafter for at least the first two years of treatment. In case of treatment discontinuation, liver tests should be pursued until normalisation of transaminase levels. For more information, reference is made to the Summary of Product Characteristics. Regarding further changes of the PI reference is made also to variation AUBAGIO EMEA/H/C/002514/II/0029. |

<div style=\"page-break-after: always\"></div>

|         | or BELTRIMS registry) and one US-based database of electronic health records (Optum Humedica Database) and postmarketing experience included in the Sanofi Global pharmacovigilance database. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data                                                                                                                                                                                                                                                                                                                                                                                                                |            |            |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
|---------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0029 | To update section 4.4 of the SmPC to add information on cases of drug-induced liver injury (DILI) observed in the postmarketing setting and section 4.8 of the SmPC to add of the adverse event DILI under the frequency unknown. During the assessment, it is considered that section 5.1 of the SmPC needs to be updated to reflect new information on pharmacological effects of teriflunomide based on newly reported proprietary data and scientific literature. The package leaflet is updated accordingly. In addition, the MAH took the opportunity to updated the PL local representatives details. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data | 21/01/2021 | 17/06/2021 | SmPC and PL | Section 4.4 has been updated to reflect new information on drug-induced liver injury (DILI). Most cases of DILI ocurred several weeks or months after the initiation of the treatment with teriflunomide. Patients with pre-exisiting liver disorders, concomitant use of hepatotoxic drugs and or a substantial alcohol consumption have a higher risk of DILI. In case of elevated liver enzymes (>3ULN) or liver injury is supected, teriflunomide theraphy should be discontinued and accelerated elimination procedure should be also considered in the case of liver injury suspected. Section 4.8 has also been updated to include DILI as ADR with a frequency unknown. Section 5.1 has been updated to reflect new information on pharmacological effects of teriflunomide based on newly reported proprietary and literature. Regarding further changes of the PI reference is made also to variation AUBAGIO EMEA/H/C/002514/II/0032. For more information, please refer to the Summary of Product Characteristics. |
| II/0033 | To update sections 4.4 and 4.8 of the SmPC regarding skin reactions in particular to drug reaction with eosinophilia and systemic symptoms (DRESS)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | 14/01/2021 | 17/06/2021 | SmPC and PL |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |

<div style=\"page-break-after: always\"></div>

|         | and to update the frequency of severe skin reactions from \"Not known\" to \"Uncommon\", following a review of the Sanofi global PV database. The Package Leaflet section 4 is updated accordingly. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data                                                                                                                                                                                                                                                                                                   |            |            |                        |                |
|---------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|----------------|
| IB/0034 | C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 18/12/2020 | n/a        |                        |                |
| II/0028 | Submission of information in relation to human experience of use of teriflunomide during pregnancy from an analysis of the data recorded in the global safety database and available sources (clinical trial cases, registries and cohort studies, literature and post-marketing pregnancy reports). The MAH updated section 2 and 4.4 of the SmPC to align with the updated annex of the guideline excipients with regards to sodium. The Labelling and Package Leaflet are updated accordingly. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data | 10/09/2020 | 18/11/2020 | SmPC, Labelling and PL | Not applicable |
| IA/0030 | B.II.d.1.a - Change in the specification parameters and/or limits of the finished product - Tightening of specification limits                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 26/03/2020 | n/a        |                        |                |

<div style=\"page-break-after: always\"></div>

| II/0025   | C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | 16/01/2020   | 18/11/2020   | Annex II        |      |
|-----------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|-----------------|------|
| IB/0026/G | This was an application for a group of variations. B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site B.II.b.1.b - Replacement or addition of a manufacturing site for the FP - Primary packaging site B.II.b.1.e - Replacement or addition of a manufacturing site for the FP - Site where any manufacturing operation(s) take place, except batch- release, batch control, primary and secondary packaging, for non-sterile medicinal products B.II.b.2.c.2 - Change to importer, batch release arrangements and quality control testing of the FP - Including batch control/testing B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging | 19/12/2019   | 18/11/2020   | Annex II and PL | site |
| IAIN/0027 | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 22/11/2019   | 18/11/2020   | SmPC and PL     |      |

<div style=\"page-break-after: always\"></div>

| IB/0024   | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                                                                                                                                                                                                                                                        | 16/05/2019   | 05/12/2019   | SmPC and PL   |                                                                                                                                                                                               |
|-----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|---------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0022   | C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority                                                                                                                                                                                                                                                                                                                                                         | 26/04/2019   | n/a          |               |                                                                                                                                                                                               |
| II/0020   | Submission of the final report from study LTS 6050. This is a phase 3 long term interventional study to document the safety of two doses of teriflunomide (7 and 14 mg) in patients with multiple sclerosis with relapses. Section 4.8 is updated to amend the frequency of nail disorder from unknown to uncommon and asthenia from unknown to common. C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority | 28/02/2019   | 05/12/2019   | SmPC and PL   | The SmPC section 4.8 has been updated as follows: To update the frequency of nail disorder from unknown to uncommon and asthenia from unknown to common. The PL has been updated accordingly. |
| IAIN/0021 | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                                                                                                                                                                                                                                                        | 11/12/2018   | 05/12/2019   | SmPC and PL   |                                                                                                                                                                                               |
| IA/0019/G | This was an application for a group of variations. A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient B.I.a.1.i - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Introduction of a new site of micronisation                                                      | 03/08/2018   | n/a          |               |                                                                                                                                                                                               |

<div style=\"page-break-after: always\"></div>

|                     | B.I.b.1.b - Change in the specification parameters                                                                                            |                       |                |                                  |                                                                                                                                                                                                                                                                       |
|---------------------|-----------------------------------------------------------------------------------------------------------------------------------------------|-----------------------|----------------|----------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IA/0018 R/0016      | and/or limits of an AS, starting material/intermediate/reagent - Tightening of specification limits Renewal of the marketing authorisation.   | 28/06/2018 22/03/2018 | n/a 28/05/2018 | SmPC, Annex II, Labelling and PL | Based on the review of data on quality, safety and efficacy, the CHMP considered that the benefit-risk balance of AUBAGIO in the approved indication remains favourable and therefore recommended the renewal of the marketing authorisation with unlimited validity. |
| PSUSA/10135 /201709 | Periodic Safety Update EU Single assessment - teriflunomide                                                                                   | 12/04/2018            | n/a            |                                  | PRAC Recommendation - maintenance                                                                                                                                                                                                                                     |
| N/0015              | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                              | 27/10/2017            | 28/05/2018     | PL                               |                                                                                                                                                                                                                                                                       |
| IB/0013             | C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation | 26/07/2017            | n/a            |                                  |                                                                                                                                                                                                                                                                       |
| IB/0014             | A.z - Administrative change - Other variation                                                                                                 | 20/07/2017            | n/a            |                                  |                                                                                                                                                                                                                                                                       |
| PSUSA/10135 /201609 | Periodic Safety Update EU Single assessment - teriflunomide                                                                                   | 21/04/2017            | 15/06/2017     | SmPC, Labelling and PL           | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUSA/10135/201609.                                                                                                                            |
| IAIN/0012           | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                | 09/06/2017            | 28/05/2018     | SmPC, Annex II and PL            |                                                                                                                                                                                                                                                                       |
| IA/0010             | B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process                                        | 02/12/2016            | n/a            |                                  |                                                                                                                                                                                                                                                                       |

<div style=\"page-break-after: always\"></div>

|                     | of the AS                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |            |            |             |                                                                                                                                                                                                                                                                                       |
|---------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/10135 /201503 | Periodic Safety Update EU Single assessment - teriflunomide                                                                                                                                                                                                                                                                                                                                                                                                                                      | 22/10/2015 | 16/12/2015 | SmPC and PL | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUSA/10135/201503.                                                                                                                                            |
| IB/0009/G           | This was an application for a group of variations. B.I.b.1.c - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Addition of a new specification parameter to the specification with its corresponding test method B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting | 16/10/2015 | n/a        |             |                                                                                                                                                                                                                                                                                       |
| PSUSA/10135 /201409 | Periodic Safety Update EU Single assessment - teriflunomide                                                                                                                                                                                                                                                                                                                                                                                                                                      | 23/04/2015 | 19/06/2015 | SmPC and PL | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUSA/10135/201409.                                                                                                                                            |
| PSUV/0005           | Periodic Safety Update                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | 25/09/2014 | 19/11/2014 | SmPC and PL | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUV/0005.                                                                                                                                                     |
| II/0003             | Update of sections 4.8 and 5.1 of the Summary of Product Characteristics (SmPC) following the completion of study TOPIC. The patient leaflet is updated accordingly. In addition, section 4.5 was updated to improve the wording related to the oral                                                                                                                                                                                                                                             | 25/09/2014 | 19/11/2014 | SmPC and PL | After the review of the data, the CHMP recommended the update of the summary of the safety profile of the product including updated frequencies of existing adverse drug reactions (ADRs) and addition of new ADRs (upper abdominal pain). In addition, the following information was |

<div style=\"page-break-after: always\"></div>

|           | contraceptive pharmacokinetics interaction. Minor editorial changes are introduced throughout the Product Information (PI). Additionally, the MAH took the opportunity to update the list of local representatives in the Package Leaflet (PL). C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data   |            |            |             | included in section 5.1 of the SmPC: The TOPIC was a double-blind, placebo-controlled study that evaluated once daily doses of teriflunomide 7 mg and 14 mg for up to 108 weeks in patients with first clinical demyelinating event (mean age 32.1 years). The primary endpoint was time to a second clinical episode (relapse). A total of 618 patients were randomized to receive 7 mg (n=205) or 14 mg (n=216) of teriflunomide or placebo (n=197). The risk of a second clinical attack over 2 two years was 35.9% in the placebo group and 24.0% in the teriflunomide 14 mg treatment group (hazard ratio: 0.57, 95% confidence interval: 0.38 to 0.87, p=0.0087). The results from the TOPIC study confirmed the efficacy of teriflunomide in RRMS (including early RRMS with first clinical demyelinating event and MRI lesions disseminated in time and space).   |
|-----------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0004   | Update of the section 4.4 with results of the second vaccination study, PDY12738 performed with vaccinations to inactivated neoantigen. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data                                                                                                           | 24/07/2014 | 19/11/2014 | SmPC        | In this variation the company added the information from two clinical studies which have shown that both the first vaccination and re-exposure to inactivated vaccine are safe and effective during treatment with AUBAGIO; however, the use of live (attenuated) vaccines should be avoided.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| IG/0454   | C.I.8.a - Introduction of or changes to a summary of Pharmacovigilance system - Changes in QPPV (including contact details) and/or changes in the PSMF location                                                                                                                                                                                                     | 17/07/2014 | n/a        |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| IAIN/0002 | C.I.12 - Inclusion or deletion of black symbol and explanatory statements for medicinal products in the                                                                                                                                                                                                                                                             | 19/12/2013 | 19/11/2014 | SmPC and PL |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |

<div style=\"page-break-after: always\"></div>

|        | list of medicinal products that are subject to additional monitoring                             |            |            |    |
|--------|--------------------------------------------------------------------------------------------------|------------|------------|----|
| N/0001 | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification) | 13/12/2013 | 19/11/2014 | PL |